PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsNewsFirst gene therapy for Duchenne muscular dystrophy approved

BioNews

First gene therapy for Duchenne muscular dystrophy approved

Published 3 July 2023 posted in News and appears in BioNews 1196

Author

Dr Maria Botcharova

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.

The US Food and Drug Administration has approved the first gene therapy for Duchenne muscular dystrophy...

The US Food and Drug Administration (FDA) has approved the first gene therapy for Duchenne muscular dystrophy (DMD).

DMD is a rare disease caused by a mutation in the gene that encodes dystrophin, a protein essential in strengthening and connecting muscle fibres. The conditions cause progressive weakening of the muscles from the age of around three, eventually impacting muscles involved in heart and lung function. It is an X-linked condition and predominantly affects boys.

'Duchenne is a relentlessly progressive, degenerative disease, robbing children of muscle function,' said Dr Jerry Mendell, paediatric neurologist at Nationwide Children's Hospital, Columbus, Ohio, who worked on developing the drug. 'ELEVIDYS can make a difference in the lives of our patients.'

Elevidys (delandistrogene moxeparvovec-rokl) was approved for children between the ages of four and five who can walk and have a confirmed mutation in the dystrophin gene. It uses an adeno-associated virus to deliver micro-dystrophin, a shortened version of the dystrophin gene, into cells, which in turn triggers production of the protein. The large size of the original dystrophin gene prevents its full-length version from being delivered using this technique.

Current treatments for DMD only address its symptoms. They include anti-inflammatory corticosteroid drugs, which may improve muscle strength, and equipment such as wheelchairs to aid mobility. A handful of targeted therapies have been approved, but they are indicated for very specific genetic mutations and need to be administered repeatedly. On the other hand, Elevidys requires only a single intravenous infusion.

Elevidys is the first gene therapy to be approved through an accelerated FDA route, reserved for the most serious conditions with an unmet need. While clinical trials showed that the drug increased the expression of micro-dystrophin, they have not shown a significant difference to motor function, which is the ultimate aim.

The FDA decision was a close one, with the drug receiving eight votes among a panel of 14 experts:

'It's a vote for hope,' FDA panellist Professor Donald Kohn from the University of California Los Angeles told Nature News. 'From a statistical standpoint, they haven't pled their case'.

Sarepta Therapeutics, the company producing Elevidys, is running a Phase III trial involving 126 patients, which is expected to show some results by the end of the year.

Existing data is based on a smaller, Phase II trial which started in 2018 and has not yet been published in a peer-reviewed journal. Each of the 41 DMD patients aged between four and seven, received a single dose of either Elevidys or a placebo. Dystrophin levels were measured at 12 weeks. If younger patients benefited the most, this may explain the age-based approval restrictions for Elevidys.

The drug is expected to cost $3.2million per patient. However, this may still prove to be cost effective compared to existing targeted therapies because of its single administration. It shows some side effects, including vomiting, nausea and worsened liver function, which needs to be monitored closely.

Sources and References

  • 22 June 2023
    US Food and Drug Administration
    FDA approves first gene therapy for treatment of certain patients with Duchenne muscular dystrophy
  • 22 June 2023
    Sarepta Therapeutics
    Sarepta Therapeutics announces FDA approval of ELEVIDYS, the first gene therapy to treat Duchenne muscular dystrophy
  • 23 June 2023
    Nature
    FDA approves first gene therapy for Duchenne muscular dystrophy, despite internal objections
  • 22 June 2023
    Reuters
    US FDA approves Sarepta's gene therapy for rare muscular dystrophy in some kids
  • 23 June 2023
    Pharmaceutical Technology
    FDA approves Duchenne gene therapy with hefty $3.2m price tag
  • 23 June 2023
    Time
    FDA approves first gene therapy for Duchenne muscular dystrophy

Related Articles

Image by Sílvia Ferreira, Cristina Lopo and Eileen Gentleman via the Wellcome Collection. Depicts a single human stem cell embedded within a porous hydrogel matrix (false colour).
CC BY 4.0
Image by Sílvia Ferreira, Cristina Lopo and Eileen Gentleman via the Wellcome Collection. Depicts a single human stem cell embedded within a porous hydrogel matrix (false-coloured cryogenic scanning electron micrograph).
News
2 October 2023 • 2 minutes read

FDA panel concludes that ALS stem cell therapy lacks evidence

by Rachel Arkell

The US Food and Drug Administration's Advisory Committee for Cellular, Tissue and Gene Therapies has voted that there is insufficient evidence that experimental stem-cell therapy for ALS is effective enough to warrant approval by the agency...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
21 August 2023 • 2 minutes read

Gene therapy for alcohol use disorder

by Dr Helen Robertson

Gene therapy could provide a one-off, sustained treatment for patients with severe alcohol use disorder, a study in monkeys suggests...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
10 July 2023 • 2 minutes read

First gene therapy for haemophilia A approved

by Tom Turner

The first gene therapy for haemophilia A has been approved for severe cases by the US Food and Drug Administration...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
20 February 2023 • 2 minutes read

First NHS recipient of gene therapy Libmeldy cured of neurodegenerative disease

by Georgia Stimpson

A toddler with a rare neurodegenerative disease is the first in the UK to be cured using gene therapy...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
14 February 2022 • 2 minutes read

NICE approves first gene therapy for neurodegenerative disorder affecting children

by Georgia Stimpson

NICE have approved a new therapy for use in the NHS in children with Metachromatic Leukodystrophy (MLD), a rare neurodegenerative genetic disorder...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
10 January 2022 • 2 minutes read

Gene therapy developed to treat limb-girdle muscular dystrophy

by Dr Holly Barker

A new gene therapy approach has shown promise in a preclinical mouse model for treating limb-girdle muscular dystrophy 2B, a rare genetic disorder which causes severe muscle weakness...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
4 May 2021 • 2 minutes read

CRISPR genome editing corrects a Duchenne muscular dystrophy deletion mutation in mice

by Dr Christina Burke

Two genome editing approaches can correct a variety of mutations associated with Duchenne muscular dystrophy, researchers have shown...

Leave a Reply Cancel reply

You must be logged in to post a comment.

« Childhood Hodgkin lymphoma survivors take longer to conceive in 20s

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels


easyfundraising
amazon

This month in News

  • Popular
  • Recent
20 November 2023 • 3 minutes read

HFEA publishes recommendations for reform of fertility law

13 November 2023 • 2 minutes read

Four BRCA mutation carriers undergo removal of ovaries during C-section 

13 November 2023 • 2 minutes read

Frequent mobile phone use linked to lower sperm count in young men

6 November 2023 • 3 minutes read

Health Council of the Netherlands recommends doubling the 14-day limit on embryo research

30 October 2023 • 2 minutes read

Government to scrap additional IVF screening for same-sex couples

27 November 2023 • 2 minutes read

Research into gene therapy reveals blood cancer risk

27 November 2023 • 2 minutes read

Polish Parliament debates reinstatement of state IVF funding

27 November 2023 • 2 minutes read

Over 100,000 DNA evidence samples must be re-tested in Australia

27 November 2023 • 2 minutes read

Childhood autism associated with infertility in parents

27 November 2023 • 2 minutes read

Unintended consequence of CRISPR/Cas9 genome editing discovered

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2023 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2023 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856